Azenta (AZTA) Projected to Post Quarterly Earnings on Wednesday

Azenta (NASDAQ:AZTA) will likely be announcing its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $145.69 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.08. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. The business had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $169.66 million. During the same period last year, the business earned $0.13 earnings per share. The business’s quarterly revenue was down 1.2% on a year-over-year basis. On average, analysts expect Azenta to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Azenta Price Performance

Shares of NASDAQ AZTA opened at $54.25 on Wednesday. Azenta has a one year low of $38.82 and a one year high of $67.86. The stock has a market capitalization of $2.48 billion, a P/E ratio of -18.27 and a beta of 1.47. The firm’s 50 day simple moving average is $49.44 and its two-hundred day simple moving average is $49.09.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AZTA. Evercore ISI cut their target price on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Needham & Company LLC cut their target price on shares of Azenta from $69.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Finally, Stephens restated an “overweight” rating and issued a $60.00 target price on shares of Azenta in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Azenta has an average rating of “Moderate Buy” and a consensus target price of $61.60.

Insider Buying and Selling

In related news, CFO Herman Cueto sold 712 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $40.07, for a total value of $28,529.84. Following the completion of the sale, the chief financial officer now owns 23,892 shares of the company’s stock, valued at $957,352.44. This trade represents a 2.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William L. Cornog acquired 12,500 shares of the stock in a transaction on Monday, November 18th. The shares were purchased at an average cost of $39.60 per share, with a total value of $495,000.00. Following the transaction, the director now directly owns 14,755 shares of the company’s stock, valued at approximately $584,298. This trade represents a 554.32 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 1,423 shares of company stock valued at $57,020 over the last quarter. 10.62% of the stock is owned by company insiders.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.